GLPwatch
Papers (10404)
Page 77 of 174, ranked by citation count.
- Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.
- GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
- Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
- Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.
- Effect of PANDER in βTC6-cell lipoapoptosis and the protective role of exendin-4.
- Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
- Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery.
- Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin.
- Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.
- GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling.
- Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy.
- Tirzepatide for overweight and obesity management.
- Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score-matched study.
- Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.
- Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
- Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.
- Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
- Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.
- Exendin-4 promotes bone formation in diabetic states via HDAC1-Wnt/β-catenin axis.
- Weight loss and body composition after compounded semaglutide treatment in a real world setting.
- Development of an <sup>111</sup>In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake.
- Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.
- Tolerability and safety of the new anti-obesity medications.
- α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.
- Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
- Initial Experience with Alternate-Day Liraglutide for Weight Regain Following Bariatric Surgery.
- Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
- Retatrutide showing promise in obesity (and type 2 diabetes).
- Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.
- Elevated blood pressure, heart rate and body temperature in mice lacking the XLαs protein of the Gnas locus is due to increased sympathetic tone.
- Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.
- Exendin-4 Promotes Schwann Cell Proliferation and Migration via Activating the Jak-STAT Pathway after Peripheral Nerve Injury.
- Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
- Exendin-4 regulates endoplasmic reticulum stress to protect endothelial progenitor cells from high-glucose damage.
- Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
- The fetal origins of the metabolic syndrome: can we intervene?
- Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.
- Tirzepatide attenuates mammary tumor progression in diet-induced obese mice.
- Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome.
- Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor Binding of a Vitamin B12 Conjugate of Exendin-4.
- Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.
- Potential contributors to variation in weight-loss response to liraglutide.
- Glucagon-like peptide-1 control of GnRH secretion in female sheep.
- A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice.
- Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
- The effects of Exendin-4 on bone marrow-derived mesenchymal cells.
- Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice.
- A Comparison of New Pharmacological Agents for the Treatment of Obesity.
- The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.
- Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
- Growth Promotion and Increased ATP-Binding Cassette Transporters Expression by Liraglutide in Triple Negative Breast Cancer Cell Line MDA-MB-231.
- Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
- Liraglutide (Saxenda) for Weight Loss.
- GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
- A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.
- Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats.
- Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.
- Role of glucagon-like peptide- 1 in vascular endothelial dysfunction.
- Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.